Clinical trial NCT07017543: Dynamics of Psychotherapy and Treatment Outcomes
Official title: Patient Capacity and Dynamic Aspects of the Psychotherapeutic Process Impacting the Course and Outcomes of Treatment
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Mental Disorders
Neurotic Disorders
Personality Disorders
Keywords: therapeutic alliance
insight
resilience
group therapy
neurotic symptoms
treatment oucome
changes in treatment
mindfulness
process-outcome research
Lead sponsor: University Hospital in Krakow
Sponsor class: OTHER
First posted: 2025-06-12
Enrollment: 89
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The study is a 3-month controlled trial that aims to measure changes in patient's capacity (mindfulness, resilience, insight, working alliance) and intensity of neurotic symptoms. The following tools are used: the Freiburg Mindfulness Inventory, the Psychological Insight Questionnaire, the Connor-Davidson Resilience Scale - Short Version, the Working Alliance Inventory - Short Version and the "O" Symptom Questionnaire. During 12-week group intervention patients are asked to fill in the appropriate set of questionnaires four times (at the beginning, two times between and at the end of treatment). The study is conducted in the Psychotherapy Unit of University Hospital in Krakow.


Eligibility criteria: Inclusion Criteria:

* diagnostic criteria for neurotic disorders (ICD-10: F40-F48.9) or personality disorders of mild to moderate severity (ICD-10: F60-F61)
* obtaining informed consent for participation in the study
* being over the age of 18

Exclusion Criteria:

* diagnosis of psychotic and/or organic disorders as well as active addictions

Primary outcomes:
measure: Resilience Level Assessed by the Connor-Davidson Resilience Scale Short Version (CD-RISC-10)
timeFrame: Week 1 (pre-treatment); Week 4 (1 month of treatment); Week 8 (2 months of treatment); Week 12 (post-treatment; end of 3-month therapy cycle)
measure: Neurotic Symptoms Questionnaire "O" (SQ-O)
timeFrame: Week 1 (pre-treatment); Week 4 (1 month of treatment); Week 8 (2 months of treatment); Week 12 (post-treatment; end of 3-month therapy cycle)
measure: Psychological Insight Assessed by the Psychological Insight Questionnaire (PIQ)
timeFrame: Week 1 (pre-treatment); Week 4 (1 month of treatment); Week 8 (2 months of treatment); Week 12 (post-treatment; end of 3-month therapy cycle)
measure: Therapeutic Alliance Level Assessed by the Working Alliance Inventory - Short Revised (WAI-SR)
timeFrame: Week 1 (pre-treatment); Week 4 (1 month of treatment); Week 8 (2 months of treatment); Week 12 (post-treatment; end of 3-month therapy cycle)
measure: Freiburg Mindfulness Inventory - Short Form (FIU-14)
timeFrame: Week 1 (pre-treatment); Week 4 (1 month of treatment); Week 8 (2 months of treatment); Week 12 (post-treatment; end of 3-month therapy cycle)
Secondary outcomes:
Other outcomes:
Locations:
city: Krakow
country: Poland
facility: University Hospital
state: Małopolska
Study officials:
References: